Novel nano-biomaterials for inhibition of respiratory syncytial virus

Research output: Chapter in Book/Report/Conference proceedingConference contribution

View graph of relations Save citation

Authors

Research units

Abstract

Respiratory syncytial virus (RSV) infection is a major concern for the population across all age groups and it is the single serotype with two major antigenic subgroups circulating together but one leads [1]. Considering published outcomes related to treatment, as well as the impact of RSV on global healthcare, a promising treatment or vaccine development remains a priority. The potential of liposomes as a carrier of active pharmacological agents was described decades ago [2-4] whilst liposomes have attracted much attention for their ability to carry antigens as well as immunomodulators [5]. Therefore, the work in this paper was aimed to prepare liposomes < 100 nm using thin film hydration followed by sonication, to effectively conjugate the anti-RSV peptide RF-482 and investigate the efficiency the liposomal formulation in presence and absence peptide RF-482 to inhibit RSV spread.

Request a copy

Request a copy

Details

Publication date1 Jan 2017
Publication titleBiotech, Biomaterials and Biomedical - TechConnect Briefs 2017
Pages75-78
Number of pages4
Volume3
ISBN (Electronic)9780998878201
Original languageEnglish
Event11th Annual TechConnect World Innovation Conference and Expo, Held Jointly with the 20th Annual Nanotech Conference and Expo, and the 2017 National SBIR/STTR Conference - Washington, United States
Duration: 14 May 201717 May 2017

Conference

Conference11th Annual TechConnect World Innovation Conference and Expo, Held Jointly with the 20th Annual Nanotech Conference and Expo, and the 2017 National SBIR/STTR Conference
CountryUnited States
CityWashington
Period14/05/1717/05/17

Bibliographic note

© 2017 TechConnect.

    Keywords

  • Liposomes, Peptide, RSV

Employable Graduates; Exploitable Research

Copy the text from this field...